Shenzhen Kaifa Technology
920029
Shanghai Yongli Belting
300230
Guomai Culture & Media
301052
WuHan Hvsen Biotechnology
300871
CHANGFU CO.,LTD
871396
CN Stock MarketDetailed Quotes
000739 Apeloa Pharmaceutical
- 15.24
- -0.09-0.59%
Market Closed Mar 28 15:00 CST
17.82BMarket Cap17.28P/E (TTM)
15.47High15.23Low110.53KlotVolume15.35Open15.33Pre Close169.54MTurnover0.95%Turnover Ratio17.28P/E (Static)1.17BShares18.9652wk High2.64P/B17.81BFloat Cap12.0152wk Low16.86Limit Up1.17BShs Float40.98Historical High13.80Limit Down1.57%Amplitude-1.06Historical Low0.32Dividend TTM15.34Avg Price58.58KlotAsk2.08%Div YieldTTM100Lot Size50.34KlotBid
Apeloa Pharmaceutical Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 4.77%12.02B | 9.30%9.29B | 7.96%6.43B | 3.65%3.2B | 8.81%11.47B | 12.57%8.5B | 19.43%5.95B | 46.83%3.09B | 17.92%10.54B | 18.00%7.55B |
| Operating revenue | 4.77%12.02B | 9.30%9.29B | 7.96%6.43B | 3.65%3.2B | 8.81%11.47B | 12.57%8.5B | 19.43%5.95B | 46.83%3.09B | 17.92%10.54B | 18.00%7.55B |
| Other operating revenue | 92.64%65.35M | ---- | -52.92%17.2M | ---- | -13.25%33.92M | ---- | 25.59%36.53M | ---- | 20.53%39.1M | ---- |
| Total operating cost | 6.14%10.86B | 11.42%8.3B | 8.85%5.65B | 4.95%2.86B | 8.05%10.23B | 10.46%7.44B | 16.33%5.19B | 40.84%2.73B | 19.50%9.47B | 20.66%6.74B |
| Operating cost | 7.34%9.16B | 13.10%7.04B | 10.76%4.84B | 9.28%2.43B | 6.30%8.53B | 9.27%6.22B | 17.31%4.37B | 44.80%2.22B | 22.46%8.02B | 24.76%5.7B |
| Operating tax surcharges | 0.39%56.31M | 2.83%38.46M | 3.02%27.69M | -37.96%8.36M | 76.59%56.09M | 47.66%37.4M | 58.92%26.88M | 41.95%13.48M | -3.89%31.76M | -14.28%25.33M |
| Operating expense | -2.76%640.23M | -7.00%399.85M | 4.85%280.58M | 13.20%152.63M | 23.01%658.42M | 8.85%429.93M | 1.88%267.59M | 7.61%134.83M | 18.28%535.26M | 5.10%394.99M |
| Administration expense | 3.09%480.94M | 1.81%364.41M | -4.07%234.37M | -9.89%123.25M | 3.66%466.55M | 4.02%357.91M | 7.53%244.33M | 17.51%136.78M | -0.85%450.06M | 11.40%344.07M |
| Financial expense | -10.34%-115.17M | 84.07%-14.05M | 32.69%-46.54M | -120.80%-3.62M | 1.30%-104.37M | 29.66%-88.19M | -34.29%-69.14M | 114.16%17.41M | -639.71%-105.75M | -732.30%-125.38M |
| -Interest expense (Financial expense) | -16.50%28.58M | -17.65%22.66M | -10.32%15.43M | -1.51%8.42M | 17.08%34.23M | 31.29%27.51M | 28.82%17.21M | 72.27%8.55M | 79.17%29.24M | 97.18%20.96M |
| -Interest Income (Financial expense) | 18.77%-92.17M | 8.58%-61.73M | -18.72%-38.72M | -10.63%-10.98M | -49.63%-113.47M | -38.51%-67.53M | -9.39%-32.62M | 25.80%-9.92M | -0.65%-75.83M | 6.28%-48.75M |
| Research and development | 2.66%641.47M | -3.42%467.2M | -10.52%314.77M | -24.38%152.94M | 17.25%624.87M | 19.44%483.76M | 24.59%351.79M | 42.14%202.24M | 19.43%532.92M | 25.98%405.01M |
| Credit Impairment Loss | 106.29%921.52K | 84.56%4.48M | -123.94%-23.46M | -21.02%-23.59M | 44.30%-14.65M | 123.30%2.43M | 43.99%-10.47M | -2,229.53%-19.49M | -22.35%-26.31M | 48.99%-10.43M |
| Asset Impairment Loss | 23.53%-70.22M | -6.51%-64.06M | -92.21%-69.04M | 25.82%-30.04M | -79.51%-91.83M | -1,279.62%-60.14M | -799.51%-35.92M | -24,708.33%-40.5M | -93.87%-51.16M | -146.57%-4.36M |
| Other net revenue | 313.82%49.2M | 166.64%27.97M | 31.69%-36.5M | 43.19%-35.08M | 64.49%-23.01M | 7.54%-41.97M | -323.80%-53.43M | -496.29%-61.76M | -164.52%-64.79M | -150.58%-45.39M |
| Fair value change income | 41,524.00%7.97M | 135.88%8.47M | 81.20%-2.54M | -167.57%-2.83M | 99.92%-19.23K | 70.01%-23.6M | 71.60%-13.49M | 203.72%4.19M | 3.30%-22.84M | -266.32%-78.71M |
| Invest income | 16.56%-18.09M | -122.64%-8.13M | 8.19%-723.42K | 72.84%-2.02M | 63.72%-21.68M | 85.59%-3.65M | -126.14%-787.93K | -178.55%-7.43M | -166.15%-59.77M | -144.40%-25.35M |
| -Including: Investment income associates | 85.44%6.06M | 450.12%2.06M | 33.43%602.32K | 59.17%-1.77M | -21.48%3.27M | -80.57%374.18K | -70.00%451.4K | -451.58%-4.33M | -67.68%4.16M | 147.79%1.93M |
| Asset deal income | -78.97%279.47K | 3,822.25%940.32K | 8,654.70%567.33K | --278.04K | -3.18%1.33M | -93.99%23.97K | -96.30%6.48K | ---- | 390.75%1.37M | -76.94%399.07K |
| Other revenue | 23.59%128.35M | 100.75%86.27M | 712.04%58.68M | 1,466.73%23.12M | 10.59%103.85M | -41.17%42.98M | -86.71%7.23M | -84.02%1.48M | 15.52%93.91M | -2.08%73.06M |
| Operating profit | -0.66%1.21B | 0.95%1.02B | 4.45%740.44M | 1.38%300.3M | 20.61%1.22B | 32.35%1.01B | 39.07%708.93M | 64.24%296.2M | -9.62%1.01B | -15.20%765.81M |
| Add:Non operating Income | 15.40%1.64M | -29.28%1.53M | -29.53%910.43K | 65.01%480.65K | -76.02%1.42M | -55.44%2.17M | -61.68%1.29M | -88.13%291.28K | 62.86%5.94M | 431.20%4.87M |
| Less:Non operating expense | -38.40%10.42M | -56.25%4.81M | -0.56%2.85M | -33.24%1.29M | 207.91%16.92M | 133.38%11M | -22.40%2.87M | 111.63%1.93M | -38.40%5.5M | 6.10%4.71M |
| Total profit | -0.11%1.2B | 1.51%1.02B | 4.40%738.5M | 1.67%299.49M | 19.03%1.2B | 31.17%1B | 38.85%707.36M | 61.95%294.56M | -9.16%1.01B | -14.85%765.96M |
| Less:Income tax cost | 15.47%172.44M | -1.91%150.46M | 7.10%113.86M | 0.94%55.78M | 552.29%149.34M | 40.88%153.38M | 46.71%106.31M | 85.44%55.26M | -85.56%22.89M | -20.77%108.87M |
| Net profit | -2.32%1.03B | 2.12%869.39M | 3.93%624.65M | 1.84%243.71M | 6.69%1.06B | 29.56%851.31M | 37.54%601.04M | 57.34%239.31M | 3.52%989.17M | -13.78%657.09M |
| Net profit from continuing operation | -2.32%1.03B | 2.12%869.39M | 3.93%624.65M | 1.84%243.71M | 6.69%1.06B | 29.56%851.31M | 37.54%601.04M | 57.34%239.31M | 3.52%989.17M | -13.78%657.09M |
| Less:Minority Profit | -712.52%-274.98K | -793.17%-264.29K | -832.16%-197.72K | -19.22%-2.29K | -1,093.06%-33.84K | 84.14%-29.59K | ---21.21K | ---1.92K | ---2.84K | ---186.53K |
| Net profit of parent company owners | -2.29%1.03B | 2.15%869.65M | 3.96%624.84M | 1.84%243.72M | 6.69%1.06B | 29.53%851.34M | 37.55%601.07M | 57.35%239.31M | 3.52%989.17M | -13.76%657.28M |
| Earning per share | ||||||||||
| Basic earning per share | -1.78%0.8864 | 2.54%0.7466 | 4.09%0.535 | 1.81%0.2084 | 7.12%0.9025 | 30.16%0.7281 | 38.51%0.514 | 58.56%0.2047 | 3.91%0.8425 | -13.50%0.5594 |
| Diluted earning per share | -1.78%0.8864 | 2.54%0.7466 | 4.09%0.535 | 1.81%0.2084 | 7.12%0.9025 | 30.16%0.7281 | 38.51%0.514 | 58.56%0.2047 | 3.91%0.8425 | -13.50%0.5594 |
| Other composite income | 282.78%10.71M | 215.37%3.57M | 128.29%874.3K | 152.70%743.15K | 329.58%2.8M | -125.97%-3.1M | -485.81%-3.09M | 1,890.26%294.09K | -855.83%-1.22M | -3,711.78%-1.37M |
| Other composite income of parent company owners | 282.78%10.71M | 215.37%3.57M | 128.29%874.3K | 152.70%743.15K | 329.58%2.8M | -125.97%-3.1M | -485.81%-3.09M | 1,890.26%294.09K | -855.83%-1.22M | -3,711.78%-1.37M |
| Total composite income | -1.56%1.04B | 2.92%872.96M | 4.61%625.52M | 2.03%244.46M | 7.10%1.06B | 29.36%848.22M | 37.00%597.95M | 57.52%239.6M | 3.37%987.95M | -13.97%655.72M |
| Total composite income of parent company owners | -1.54%1.04B | 2.94%873.22M | 4.64%625.72M | 2.03%244.46M | 7.10%1.06B | 29.32%848.25M | 37.01%597.97M | 57.52%239.6M | 3.37%987.95M | -13.94%655.91M |
| Total composite income of minority owners | -712.52%-274.98K | -793.17%-264.29K | -832.16%-197.72K | -19.22%-2.29K | -1,093.06%-33.84K | 84.14%-29.59K | ---21.21K | ---1.92K | ---2.84K | ---186.53K |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | Hexin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Hexin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Hexin Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
